Mereo BioPharma director to step down at 2026 AGM

Mereo BioPharma Group plc reported that Dr. Annalisa Jenkins has informed the company she will not stand for re-election to its Board of Directors at the 2026 annual general meeting of shareholders scheduled for May 14, 2026.

Rhea-AI Filing Summary

Mereo BioPharma Group plc reported that Dr. Annalisa Jenkins has informed the company she will not stand for re-election to its Board of Directors at the 2026 annual general meeting of shareholders scheduled for May 14, 2026.

She will continue to serve as a director until her current term expires immediately prior to that meeting. The company stated that Dr. Jenkins’ decision is not due to any disagreement with the company or the board regarding operations, policies, or practices, indicating a planned transition rather than a dispute-driven departure.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What board change did Mereo BioPharma (MREO) disclose in this 8-K?

Mereo BioPharma disclosed that director Dr. Annalisa Jenkins will not stand for re-election at the 2026 annual general meeting. She will remain on the board until her term expires immediately before that meeting, indicating an orderly and planned transition in board composition.

When will Dr. Annalisa Jenkins leave the Mereo BioPharma (MREO) board?

Dr. Annalisa Jenkins will leave the board immediately prior to Mereo BioPharma’s 2026 annual general meeting on May 14, 2026. Until that date, she continues to serve as a director, ensuring continuity in governance during the transition period leading up to the shareholder meeting.

Did Dr. Jenkins resign over a disagreement with Mereo BioPharma (MREO)?

The company stated that Dr. Jenkins’ decision not to stand for re-election did not result from any disagreement with the company or the board on operations, policies, or practices. This language signals a voluntary, non-dispute-related decision rather than a conflict-driven or contentious departure.

What SEC item does this Mereo BioPharma (MREO) filing relate to?

The disclosure falls under Item 5.02, which covers departures of directors or certain officers, elections of directors, appointments of officers, and compensatory arrangements. In this case, it specifically addresses a director’s decision not to stand for re-election at the upcoming annual general meeting.

When is Mereo BioPharma’s 2026 annual general meeting scheduled?

Mereo BioPharma’s 2026 annual general meeting of shareholders is scheduled for May 14, 2026. Dr. Annalisa Jenkins will serve as a director until immediately before this meeting, after which her term will end in line with her decision not to seek re-election.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/27/2026 - 06:10 AM Learn about SEC filing dates

false0001719714trueX000-00000000001719714us-gaap:CommonStockMember2026-03-262026-03-2600017197142026-03-262026-03-260001719714dei:AdrMember2026-03-262026-03-26

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

Current Report

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 26, 2026

MEREO BIOPHARMA GROUP PLC

(Exact name of registrant as specified in its charter)

England and Wales		001-38452		Not Applicable
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

4th Floor, One Cavendish Place,

London, W1G 0QF

United Kingdom

(Address of principal executive offices, including zip code)

+44-333-023-7300

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of each exchange on which registered
American Depositary Shares, each representing five Ordinary Shares, par value £0.003 per share		MREO		The Nasdaq Stock Market LLC
Ordinary Shares, nominal value £0.003 per share*		*		The Nasdaq Stock Market LLC

*Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Stock Market LLC.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 - Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March 26, 2026, Dr. Annalisa Jenkins informed Mereo BioPharma plc. (the “Company”) that she will not stand for re-election as a Director of the Board of Directors (the “Board”) of the Company at the Company’s 2026 annual general meeting of shareholders (the “2026 AGM”), scheduled for May 14, 2026. Dr. Jenkins will continue to serve out the remainder of her term, which will expire immediately prior to the 2026 AGM. Dr. Jenkins’ decision not to stand for re-election did not result from any disagreement with the Company or the Board on any matter relating to the Company’s operations, policies or practices.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

	MEREO BIOPHARMA GROUP PLC
Date: March 27, 2026	By:	/s/ Charles Sermon
		Name:	Charles Sermon
		Title:	General Counsel

Filing Exhibits & Attachments

1 document

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 56.9 KB